Alpha-dihydroergocryptine in the long-term therapy of Parkinson's disease

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 10, 2004, Pages 647-654

  Mailland, Enrico ^a   Magnani, Paola ^b   Ottillinger, Bertram ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Polichem SA   (Switzerland)

^c Ottillinger Life Sciences   (Germany)

Author keywords

Alpha dihydroergocryptine, observational study, safety profile in Parkinson's disease; CAS 14271 05 7; CAS 59 92 7; Cripar ; Levodopa; Parkinson's disease

Indexed keywords

CRIPAR; DIHYDROERGOCRYPTINE; LEVODOPA;

ABDOMINAL PAIN; ADULT; AGED; ALLERGY; ARTICLE; ATAXIA; BILIARY TRACT DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; DIARRHEA; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION IMPROVEMENT; HALLUCINATION; HUMAN; HYPERBILIRUBINEMIA; HYPERHIDROSIS; HYPOTENSION; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PSYCHOSIS; QUESTIONNAIRE; SLEEP DISORDER; SYMPTOM; THORAX PAIN; TREATMENT OUTCOME; TREMOR; VASCULAR DISEASE; VERTIGO; VOMITING; XEROSTOMIA;

EID: 7044251642     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297016     Document Type: Article

References (41)

1. Raschetti, R., Spila-Alegiani, S., Vanacore, N. et al., Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol. Scand. 97, 20 (1998)
2. Mytilineou, C., Walker, R. H., JnoBaptiste, R. et al., Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther. 304, 792 (2003)
3. th ed., pp. 549-568, McGraw-Hill, New York (2001)
4. Canonico, P. L., D2 dopamine receptor activation reduces free [3H]arachidonate release induced by hypophysiotropic peptides in anterior pituitary cells. Endocrinology 125, 1180 (1989)
5. Maggioni, A., Peroglio, F., Olgiati, V. et al., The pharmacological receptor binding affinity profile of Daverium, a new neuroprotective agent. XXVII National Congress of the Società Italiana di Farmacologia, Torino 1994 (Abstract)
6. st International Congress of Neuroendocrinology, San Francisco, July 9-11, 1986; 60 (Abstract)
7. Neusch, C., Bohme, V., Riesland, N. et al., The dopamine D2 receptor agonist alpha-dihydroergocryptine modulates voltage-gated sodium channels in the rat caudate-putamen. J. Neural Transm. 107, 531 (2000)
8. Benzi, G., Pastoris, O., Gorini, A. et al., Influence of aging on the acute depletion of reduced gluthatione induced by electrophilic agents. Neurobiol. Aging 12, 227 (1991)
9. Benzi, G., Pastoris, O., Marzatico, F. et al., Age-related effect induced by oxidative stress on the cerebral glutathione system. Neurochem. Res. 14, 473 (1989)
10. Benzi, G., Pastoris, O., Marzatico, F. et al., Influence of aging and drug treatment on the cerebral glutathione system. Neurobiol. Aging 9, 371 (1988)
11. Benzi, G., Pastoris, O., Villa, R. F., Changes induced by aging and drug treatment on cerebral enzymatic antioxidant system. Neurochem. Res. 13, 467 (1988)
12. Marzatico, F., Café, C., Taborelli, M. et al., Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. Neurochem. Res. 18, 1101 (1993)
13. Curti, D., Izzo, E., Benzi, G. et al., Alteration of pallidal cholinergic activity in MPTP-treated monkeys: effect of dihydro-α-ergocryptine (DEK). Neurosci. Lett. 168, 213 (1994)
14. Bernocchi, G., Gerzeli, G., Scherini, E. et al., Neuroprotective effects of α-dihydroergocryptine against damages in the substantia nigra caused by severe tretament with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Neuropathol. 85, 404 (1993)
15. Medico, M., De Vivo, S., Tomasello, C. et al., Behavioral and neurochemical effects of dopaminergic drugs in models of brain injury. Eur. Neuropsychopharmacol. 12, 187 (2002)
16. Mailland, F., Coppi, G., Zanotti, A., Pharmacokinetics and Pharmacodynamics of Dihydroergokryptine in humans. Second European Winter Conference, Madonna di Campiglio, March 12-18, 1989. Gynecol. Endocrinol. 3 (Suppl. 1), FC99 (1989) (Abstract)
17. Palermo, A., Colombo, F., Bertalero, P. et al., Action of dihydroergokryptine (DEK) on blood pressure (BP) and norepinephrine (NE) release from nerve endings in humans. IV World Conference on Clinical Pharmacology and Therapeutics, Mannheim/Heidelberg, July 23-28, 1989 (Abstract)
18. Cripar®. Summary of Product Characteristics (Fachin-formation) of the Swiss Pharmacopoea. Documed AG, Basel (2001)
19. Battistin, L., Bardin, PG., Ferro-Milone, F. et al., Alpha- dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study. Acta Neurol. Scand. 99, 36 (1999)
20. Bergamasco, B., Frattola, L., Muratorio, A. et al., Alpha- dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol. Scand. 101, 372 (2000)
21. Martignoni, E., Pacchetti, C., Sibilla, L. et al., Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial. Clin. Neuropharmacol. 14, 78 (1991)
22. Bergamasco, B., Frattola, L., Muratorio, A. et al., -dihydroergokryptine in the treatment of de novo parkinsonian patients: eighteen-month follow-up. Poli Internal Report (1997)
23. Rodriguez, M., Mailland, F., Obeso, J. A. et al., Dihydroergokryptine in Parkinson's disease: double-blind study versus bromocriptine. Proceedings of the European Conference on Parkinson's Disease and Extrapyramidal Disorders. Rome, July 10-14, 1990; pp. 19-29, John Libbey CIC, Rome (1991)
24. Scarzella, L., Lopiano, L., Bergamasco, B., Dihydroergocriptine in the treatment of Parkinsonism: a 36-month follow up. Proceedings of the European Conference on Parkinson's Disease and Extrapyramidal Disorders. Rome, July 10-14, 1990; pp. 359-368, John Libbey CIC, Rome (1991)
25. Rascol, O., Payoux, P., Ferreira, J. et al., The management of patients with early Parkinson's disease. Parkinsonism and Related Disorders 9, 61 (2002)
26. NN. DA agonists - Ergot derivatives: Dihidroergocryptine (DHEC). Movement Disorders 17 (Suppl. 4), S72 (2002)
27. The European Agency for the Evaluation of Medicinal Products. Notice to Marketing Authorisation Holders. Pharmacovigilance Guidelines. CPMP/PhVWP/108/99 corr., Chapter 5
28. th ed., pp. 1021-1036, McGraw-Hill, New York (2001)
29. Rascol, O., Nutt, J. G., Blin, O. et al., Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch. Neurol. 58, 249 (2001)
30. Ergoloid mesylates (Systemic). USP DI® Drug information for the health care professional. Micromedex Thomson Healthcare, Englewood (2001)
31. th ed., pp. 215-268, McGraw-Hill, New York (2001)
32. Luchsinger, A., Velasco, M., Urbina, A. et al., Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients. J. Clin. Pharmacol. 32, 55 (1992)
33. Goetz, C. G., Burke, P. F., Leurgans, S. et al., Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch. Neurol. 58, 209 (2001)
34. th ed., pp. 485-520, McGraw-Hill, New York (2001)
35. Motles, E., Tetas, M., Gomez, A., Behavioral effects evoked by SKF 38393 and LY 171555 in adult cats. Physiol. Behav. 57, 983 (1995)
36. Homann, C. N., Wenzel, K., Suppan, K. et al., Sleep attacks in patients taking dopamine agonists: review. Br. Med. J. 324, 1483 (2002)
37. Montastruc, J. L., Brefel-Courbon, C., Senard, J. M. et al., Sudden sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiological study. Mov. Disord. 15, 130 (2000)
38. Montastruc, J. L., Brefel-Courbon, C., Senard, J. M. et al., Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiological study. Clin. Neuropharmacol. 24, 181 (2001)
39. Carvey, P. M., McGuire, S. O., Ling, Z. D., Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat. Disord. 7, 213 (2001)
40. Yoshioka, M., Tanaka, K., Miyazaki, I. et al., The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci. Res. 43, 259 (2002)
41. Tatsch, K., Poepperl, G., Ruzicka, E. et al., Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of disease progression with dopamine transporter SPECT. Proc. 7th International Congress of Parkinson's Disease and Movement Disorders, Miami (USA), Nov. 2002